NCT01656759View on ClinicalTrials.gov

Use of a Novel Fibrin Sealant in Total Knee Arthroplasty

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

73

Participants

Timeline

Start Date

May 31, 2012

Primary Completion Date

December 31, 2014

Study Completion Date

August 31, 2015

Conditions
OsteoarthritisIntraoperative Bleeding
Interventions
DRUG

Evicel Fibrin Spray

10cc syringe dose, once at the end of TKA

Trial Locations (1)

60304

Rush Oak Park Hospital, Oak Park

All Listed Sponsors
lead

Rush University Medical Center

OTHER

NCT01656759 - Use of a Novel Fibrin Sealant in Total Knee Arthroplasty | Biotech Hunter | Biotech Hunter